Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02140268 · ClinicalTrials.gov registry record · Phase 1

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

A Phase 1 study of Healthy Volunteers, sponsored by Ardelyx.

Completed
Registry status
Phase 1
Development phase
65
Enrollment target
1
Study location

NCT02140268 is a Phase 1 study of Healthy Volunteers that has completed, run by Ardelyx. The registered enrollment target is 65 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02140268, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Ardelyx.

COMPLETED
Registry status
Phase 1
Development phase
65 participants
Enrollment target
1
Study location

Study Summary

A Study to Evaluate the Effects of oral repeated doses of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Conditions Studied

Interventions

  • DRUG Midazolam
  • DRUG AZD1722
  • DRUG AZD1722 and Midazolam

Study Locations (1)

Kansas

  • Research Site - Overland Park

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2014-05
Est. Completion 2014-08
Phase Phase 1

Sponsor

Ardelyx

25 total trials

What the Registry Record Tells You About NCT02140268

The ClinicalTrials.gov registry entry for NCT02140268 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (87% lower). The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Midazolam is the first listed.

NCT02140268 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT02140268 about?

NCT02140268 is a clinical study titled "To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers". A Study to Evaluate the Effects of oral repeated doses of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

What is the current status of trial NCT02140268?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2014-05. Estimated completion is 2014-08.

What conditions does trial NCT02140268 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT02140268?

The interventions under investigation include: Midazolam (DRUG), AZD1722 (DRUG), AZD1722 and Midazolam (DRUG).

Who is sponsoring clinical trial NCT02140268?

This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02140268 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.